My guess is that J&J has seen the data on the mid stage drugs and that data is very solid. Get AMBS to show MANF works in early or mid stage clinical trials and we might see a multi billion dollar buy out. But that's not going to happen for another 2-4 years imo. MANF is too early in the development stage determine if it has any worth what so ever.